earticle

영어

This systematic review aimed to assess the clinical evidence supporting the use of an herbal drug, Bojungikgi-Tang (BIT) for the treatment of atopic dermatitis (AD). Eleven databases, including PubMed, EMBASE, and the CENTRAL, were searched from their inception to December 2019. All randomized controlled trials that reported on the effects of BIT on AD, without language restrictions, were included. The methodological quality of and risk of bias in the trials were assessed using the Cochrane Collaboration tool. We identified 2,674 studies, of which two met the inclusion criteria. The overall risk of bias in the included trials was relatively low or unclear. There were statistically significant improvements in the oozing and crust score (p=0.04) and total equivalent amount (TEA) of topical agents (p=0.02) in the BIT group in comparison to those in the placebo group. The evidence suggests that BIT can significantly reduce the oozing and crust symptoms and TEA of topical agents compared with placebo. However, the limited number of trials and the small effect size make it difficult to draw firm conclusions. Trial registration number: CRD42018105173